Amgen Inc. (BVMF:AMGN34)

Market Cap	958.96B
Revenue (ttm)	191.70B
Net Income (ttm)	37.33B
Shares Out	n/a
EPS (ttm)	68.93
PE Ratio	25.69
Forward PE	16.19
Dividend	1.29 (2.03%)
Ex-Dividend Date	Aug 21, 2025

Volume	6,203
Average Volume	866
Open	63.55
Previous Close	63.13
Day's Range	63.55 - 63.65
52-Week Range	51.63 - 75.12
Beta	0.46
RSI	72.90
Earnings Date	Nov 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: AMGN34

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD